Genmab — Juni 2018

[bibob]

@Roy. Tak for svar. Der er nok mange her der ikke kan finde ud af Genmab's/ jnj's ageren i disse tider. Det burde vel være ret simpelt at sige at " this is not a final decision " og så komme med en forklaring hvad der nu skal ske. Markedet reagerer altid negativt på tvivls spørgsmål. Og er der noget Genmab ikke har brug for nu er det tvivl.

[gentogen]

Så det japanske blev submitted d. 24/5 hvorefter Genmabs meddelelse kom 26/4

[gentogen]

5

[StockBull]

Bibob. Taktik fra JNJ. Mon ikke snart de kommer med et bud omkring de 1500

[Raffles]

@Gentogen, jep - sådan læser jeg datoerne!!

[E_L]

yeah; take-over-rumour-time again - Let's go, and don't be shy, use some creativity please

[Legolas23]

Er der én der gider skubbe til pickup'n

[royal]

Nogen der er oppe til at lytte med kl 0100? http://ir.genmab.com/events.cfm

[E_L]

JNJ webcast with president Janssen oncology Tom Cavenaugh
president immunology scott white
http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=1068667

[royal]

Dara ikke dømt ude af solide.

[Mcjean]

link eller hvis det er fra webcast har du så tidspunkt for statement?

[royal]

ca. midtvejs

[royal]

16,30 inde

[Mcjean]

I linket med JNJ, den varer 4timer og 42min

[E_L]

"look at the development we did we darzalex"; proud of their execution

[E_L]

earlier lines darzalex MM, outside MM amyloidosis and CLL(AML and prostate cancer?)
mentioned BCMA CD3

[royal]

Just a moment...

(www.investor.jnj.com)

[E_L]

Q Dara phenomenal launch and the data has been really nothing less then extraordinary; but it does seem that this market is changing; with
competitve headwinds from car-t how do you see this impacting darzalex

[E_L]

A we absolutely see this complimentary, cart potentially replacing stem cell transplant
combination therapy in the frontline with Dara

[E_L]

Q you also talked about the potential Darzalex in solid tumours. Now halting studies
does this change your view at all hat dara can be used as an IO thereapy?